Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 432

1.

Adipose-derived mesenchymal stem cells (AdMSC) for the treatment of secondary-progressive multiple sclerosis: A triple blinded, placebo controlled, randomized phase I/II safety and feasibility study.

Fernández O, Izquierdo G, Fernández V, Leyva L, Reyes V, Guerrero M, León A, Arnaiz C, Navarro G, Páramo MD, Cuesta A, Soria B, Hmadcha A, Pozo D, Fernandez-Montesinos R, Leal M, Ochotorena I, Gálvez P, Geniz MA, Barón FJ, Mata R, Medina C, Caparrós-Escudero C, Cardesa A, Cuende N; Research Group Study EudraCT 2008-004015-35.

PLoS One. 2018 May 16;13(5):e0195891. doi: 10.1371/journal.pone.0195891. eCollection 2018.

2.

Untargeted Analysis of Semipolar Compounds by LC-MS and Targeted Analysis of Fatty Acids by GC-MS/GC-FID: From Plant Cultivation to Extract Preparation.

Bénard C, Acket S, Rossez Y, Fernandez O, Berton T, Gibon Y, Cabasson C.

Methods Mol Biol. 2018;1778:101-124. doi: 10.1007/978-1-4939-7819-9_8.

PMID:
29761434
3.

Attitude Toward Organ Donation and Transplantation in Veterinary Students: A Multicenter and Stratified Study in Spain.

Martínez-Alarcón L, Ríos A, Ramis G, Gómez-Laguna J, Moll X, Falceto V, San Román-Acaso F, San Román-Llorens F, Quereda JJ, Herrero-Medrano JM, Mendonça L, Martin-Barrasa JL, Fernández OM, López-Navas AI, Hernández AM, Muñoz A, Ramírez P, Parrilla P.

Transplant Proc. 2018 Mar;50(2):362-365. doi: 10.1016/j.transproceed.2017.11.068.

PMID:
29579804
4.

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.

Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, Vermersch P, Arnold DL, Arnould S, Scherz T, Wolf C, Wallström E, Dahlke F; EXPAND Clinical Investigators.

Lancet. 2018 Mar 31;391(10127):1263-1273. doi: 10.1016/S0140-6736(18)30475-6. Epub 2018 Mar 23.

PMID:
29576505
5.

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.

Kapoor R, Ho PR, Campbell N, Chang I, Deykin A, Forrestal F, Lucas N, Yu B, Arnold DL, Freedman MS, Goldman MD, Hartung HP, Havrdová EK, Jeffery D, Miller A, Sellebjerg F, Cadavid D, Mikol D, Steiner D; ASCEND investigators.

Lancet Neurol. 2018 May;17(5):405-415. doi: 10.1016/S1474-4422(18)30069-3. Epub 2018 Mar 12.

PMID:
29545067
6.

Financial protection in Europe: a systematic review of the literature and mapping of data availability.

Yerramilli P, Fernández Ó, Thomson S.

Health Policy. 2018 May;122(5):493-508. doi: 10.1016/j.healthpol.2018.02.006. Epub 2018 Feb 19. Review.

7.

Dabrafenib plus trametinib for compassionate use in metastatic melanoma: A STROBE-compliant retrospective observational postauthorization study.

Martín Algarra S, Soriano V, Fernández-Morales L, Berciano-Guerrero MÁ, Mujika K, Manzano JL, Puértolas Hernández T, Soria A, Rodríguez-Abreu D, Espinosa Arranz E, Medina Martínez J, Márquez-Rodas I, Rubió-Casadevall J, Ortega ME, Jurado García JM, Lecumberri Biurrun MJ, Palacio I, Rodríguez de la Borbolla Artacho M, Altozano JP, Castellón Rubio VE, García A, Luna P, Ballesteros A, Fernández O, López Martín JA, Berrocal A, Arance A.

Medicine (Baltimore). 2017 Dec;96(52):e9523. doi: 10.1097/MD.0000000000009523.

8.

Survey of diagnostic and treatment practices for multiple sclerosis (MS) in Europe. Part 2: Progressive MS, paediatric MS, pregnancy and general management.

Fernández O, Delvecchio M, Edan G, Fredrikson S, Giovannoni G, Hartung HP, Havrdova E, Kappos L, Pozzilli C, Soerensen PS, Tackenberg B, Vermersch P, Comi G.

Eur J Neurol. 2018 May;25(5):739-746. doi: 10.1111/ene.13581. Epub 2018 Feb 28.

PMID:
29356206
9.

Combination of pegylated liposomal doxorubicin plus gemcitabine in heavily pretreated metastatic breast cancer patients: Long-term results from a single institution experience.

Martin-Romano P, Baraibar I, Espinós J, Legaspi J, López-Picazo JM, Aramendía JM, Fernández OA, Santisteban M.

Breast J. 2017 Dec 29. doi: 10.1111/tbj.12975. [Epub ahead of print]

PMID:
29286192
10.

EVALUATION OF ENEMAS CONTAINING SUCRALFATE IN TISSUE CONTENT OF MUC-2 PROTEIN IN EXPERIMENTAL MODEL OF DIVERSION COLITIS.

Fernandez OOA, Pereira JA, Campos FG, Araya CM, Marinho GE, Novo RS, Oliveira TS, Franceschi YT, Martinez CAR.

Arq Bras Cir Dig. 2017 Apr-Jun;30(2):132-138. doi: 10.1590/0102-6720201700020012. English, Portuguese.

11.

Cross-reactivity of antibodies against interferon beta in multiple sclerosis patients and interference of the JAK-STAT signaling pathway.

Hurtado-Guerrero I, Pinto-Medel MJ, Urbaneja P, Rodriguez-Bada JL, Ortega-Pinazo J, Serrano P, Fernández Ó, Leyva L, Oliver-Martos B.

Sci Rep. 2017 Nov 29;7(1):16585. doi: 10.1038/s41598-017-16828-x.

12.

Is there a change of paradigm towards more effective treatment early in the course of apparent high-risk MS?

Fernández Ó.

Mult Scler Relat Disord. 2017 Oct;17:75-83. doi: 10.1016/j.msard.2017.07.003. Epub 2017 Jul 3. Review.

13.

Treatment satisfaction with injectable disease-modifying therapies in patients with relapsing-remitting multiple sclerosis (the STICK study).

Fernández O, Duran E, Ayuso T, Hernández L, Bonaventura I, Forner M; STICK Study Investigators Group.

PLoS One. 2017 Oct 19;12(10):e0185766. doi: 10.1371/journal.pone.0185766. eCollection 2017.

14.

Profiling gene expression of antimony response genes in Leishmania (Viannia) panamensis and infected macrophages and its relationship with drug susceptibility.

Barrera MC, Rojas LJ, Weiss A, Fernandez O, McMahon-Pratt D, Saravia NG, Gomez MA.

Acta Trop. 2017 Dec;176:355-363. doi: 10.1016/j.actatropica.2017.08.017. Epub 2017 Aug 24.

PMID:
28843396
15.

Global methylation correlates with clinical status in multiple sclerosis patients in the first year of IFNbeta treatment.

Pinto-Medel MJ, Oliver-Martos B, Urbaneja-Romero P, Hurtado-Guerrero I, Ortega-Pinazo J, Serrano-Castro P, Fernández Ó, Leyva L.

Sci Rep. 2017 Aug 18;7(1):8727. doi: 10.1038/s41598-017-09301-2.

16.

The HLA DRB1*03:01 allele is associated with NMO regardless of the NMO-IgG status in Brazilian patients from Rio de Janeiro.

Alvarenga MP, Fernandez O, Leyva L, Campanella L, Vasconcelos CF, Alvarenga M, Papais Alvarenga RM.

J Neuroimmunol. 2017 Sep 15;310:1-7. doi: 10.1016/j.jneuroim.2017.05.018. Epub 2017 May 31.

PMID:
28778431
17.

Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM.

Fernández Ó, Giovannoni G, Fox RJ, Gold R, Phillips JT, Potts J, Okwuokenye M, Marantz JL.

Clin Ther. 2017 Aug;39(8):1671-1679. doi: 10.1016/j.clinthera.2017.06.012. Epub 2017 Jul 25.

18.

Estimate of the cost of multiple sclerosis in Spain by literature review.

Fernández O, Calleja-Hernández MA, Meca-Lallana J, Oreja-Guevara C, Polanco A, Pérez-Alcántara F.

Expert Rev Pharmacoecon Outcomes Res. 2017 Aug;17(4):321-333. doi: 10.1080/14737167.2017.1358617. Epub 2017 Jul 28. Review.

PMID:
28726515
19.

Review of the novelties from the 32nd ECTRIMS Congress, 2016, presented at the 9th Post-ECTRIMS Meeting (II).

Fernandez O, Oterino A, Oreja-Guevara C, Prieto JM, Mendibe-Bilbao MM, Garcia-Merino JA, Ramio-Torrenta L, Ginestal R, Meca-Lallana JE, Romero-Pinel L, Munoz D, Oliva-Nacarino P, Calles-Hernandez MC, Izquierdo G, Martinez-Gines ML, Saiz A, Comabella M, Casanova-Estruch B, Brieva L, Arroyo R, Rodriguez-Antiguedad A.

Rev Neurol. 2017 Jul 16;65(2):75-84. Spanish, English.

PMID:
28675259
20.

Leaf Starch Turnover Occurs in Long Days and in Falling Light at the End of the Day.

Fernandez O, Ishihara H, George GM, Mengin V, Flis A, Sumner D, Arrivault S, Feil R, Lunn JE, Zeeman SC, Smith AM, Stitt M.

Plant Physiol. 2017 Aug;174(4):2199-2212. doi: 10.1104/pp.17.00601. Epub 2017 Jun 29.

Supplemental Content

Loading ...
Support Center